CA2451248A1 - Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques - Google Patents

Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques Download PDF

Info

Publication number
CA2451248A1
CA2451248A1 CA002451248A CA2451248A CA2451248A1 CA 2451248 A1 CA2451248 A1 CA 2451248A1 CA 002451248 A CA002451248 A CA 002451248A CA 2451248 A CA2451248 A CA 2451248A CA 2451248 A1 CA2451248 A1 CA 2451248A1
Authority
CA
Canada
Prior art keywords
composition
hyaluronic acid
inhibitor
hyaluronidase
encapsulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002451248A
Other languages
English (en)
Inventor
Jonathan Thompson
Anna Gosiewska
Susan Niemiec
Sridevi Dhanaraj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DePuy International Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2451248A1 publication Critical patent/CA2451248A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition et une méthode de traitement de l'arthrite, ladite composition comprenant au moins un glycosaminoglycane combiné à au moins un inhibiteur d'hyaluronidase. Dans un mode de réalisation préféré, la présente invention concerne une composition et une méthode de traitement de l'arthrite, ladite composition comprenant au moins un glycosaminoglycane qui comprend au moins de l'acide hyaluronique combiné à au moins un inhibiteur d'hyaluronidase sélectionné dans le groupe constitué d'héparane sulfate, de dextrane sulfate et de xylose sulphate. Dans un autre mode de réalisation préféré encore, la présente invention concerne une composition et une méthode de traitement de l'arthrite, ladite composition comprenant de l'acide hyaluronique co-encapsulé avec un inhibiteur d'hyaluronidase présent dans les liposomes. L'acide hyaluronique présent dans la composition confère les propriétés de viscosupplément à l'articulation. La fonction de l'inhibiteur d'hyaluronidase est d'agir en tant qu'un conservateur, et de protéger l'acide hyaluronique contre la dégradation prématurée au niveau de l'articulation. L'encapsulation liposomale et la libération de ladite composition sert de dépôt à libération lente pour l'acide hyaluronique et de l'inhibiteur d'hyaluronidase. Ladite invention concerne par conséquent un moyen d'administration stable et de longue durée d'acide hyaluronique (HA) de poids moléculaire élevé au niveau de l'articulation. L'efficacité thérapeutique de l'acide hyaluronique encapsulé dans le liposome avec l'inhibiteur d'hyaluronidase est supérieur à une simple injection d'acide hyaluronique. La méthode de traitement préférée est une injection intra-articulaire d'un mélange d'acide hyaluronique et d'un inhibiteur d'hyaluronidase, éventuellement encapsulés dans des liposomes. Le traitement est plus efficace que les traitements actuellement disponibles reposant sur le seul HA.
CA002451248A 2001-06-25 2002-06-20 Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques Abandoned CA2451248A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30073401P 2001-06-25 2001-06-25
US60/300,734 2001-06-25
US74102A 2002-06-06 2002-06-06
USDEP-741 2002-06-06
PCT/US2002/019718 WO2003000191A2 (fr) 2001-06-25 2002-06-20 Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques

Publications (1)

Publication Number Publication Date
CA2451248A1 true CA2451248A1 (fr) 2003-01-03

Family

ID=26668090

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002451248A Abandoned CA2451248A1 (fr) 2001-06-25 2002-06-20 Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques

Country Status (4)

Country Link
EP (1) EP1423081A4 (fr)
JP (1) JP2005521629A (fr)
CA (1) CA2451248A1 (fr)
WO (1) WO2003000191A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4703948B2 (ja) * 2003-05-20 2011-06-15 丸善製薬株式会社 抗アレルギー剤、抗老化剤及び抗老化用皮膚外用剤
US20060040894A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid
AU2013270451B2 (en) * 2005-10-03 2016-05-12 Mark A. Pinsky Compositions and methods for improved skin care
US8378064B2 (en) 2006-05-19 2013-02-19 Trustees Of Boston University Hydrophilic polymers as medical lubricants and gels
US20100323985A1 (en) * 2007-05-11 2010-12-23 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
US20110263521A1 (en) * 2007-05-11 2011-10-27 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
ITMI20072348A1 (it) 2007-12-17 2009-06-18 Medichem Srl Metodo per la rigenerazione cellulare di acido ialuronico e relativa composizione cosmetica
AU2009249403A1 (en) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
ITMI20090779A1 (it) * 2009-05-08 2010-11-08 Vitrupharm Srl Composizioni nutrizionali a base di resveratrolo cisteina o suoi derivati o metaboliti e astaxantina
US9402857B2 (en) 2009-07-23 2016-08-02 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US9913810B2 (en) 2009-07-23 2018-03-13 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and astaxanthin
US9216164B2 (en) 2009-07-23 2015-12-22 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US8481072B2 (en) 2009-07-23 2013-07-09 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9399047B2 (en) 2009-07-23 2016-07-26 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and roe extract
US9238043B2 (en) 2009-07-23 2016-01-19 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using algae based oils
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
BR112012011336A2 (pt) * 2009-10-22 2018-10-16 Api Genesis Llc Composições compreendendo flavonoides, seu método de preparação, adesivo para aplicação de flavonoide, métodos de produção de flavonoide hidratado,métodos de preparação de formulação tópica, e uso de flavonoide
WO2011160146A1 (fr) * 2010-06-23 2011-12-29 Croma-Pharma Gesellschaft M.B.H. Préparation pharmaceutique contenant du dextrane et de l'hyaluronate de sodium pour le traitement de troubles articulaires
US8716204B2 (en) 2010-07-27 2014-05-06 Zimmer, Inc. Synthetic synovial fluid compositions and methods for making the same
ITRM20100614A1 (it) * 2010-11-24 2012-05-25 D M G Italia S R L Preparazioni farmaceutiche dell acido 18 beta glicirretico e/o di suoi derivati per infiltrazioni intrarticolari per il trattamento delle artropatie infiammatorie
FR2991876B1 (fr) 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
CA2995403A1 (fr) * 2015-08-13 2017-02-16 Bernard Stoffel Composition pour le traitement d'affections articulaires
DE102016208567A1 (de) * 2016-05-19 2017-11-23 Heraeus Medical Gmbh Polymerlösung zur Viscosupplementation
MY197149A (en) 2017-08-22 2023-05-26 Moebius Medical Ltd Liposomal formulation for joint lubrication
CN109758607B (zh) * 2019-03-08 2021-07-27 宁夏妙朗生物科技有限公司 抵抗透明质酸酶水解的交联透明质酸凝胶

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US4743596A (en) * 1987-06-16 1988-05-10 Lapin Alfred R Anti-arthritic preparation
DK191889D0 (da) * 1989-04-20 1989-04-20 Bukh Meditec Kosmetisk middel
CA2345641A1 (fr) * 1998-09-28 2000-04-06 Merck & Co., Inc. Procede de traitement de maladies inflammatoires par administration d'un inhibiteur de la thrombine
US6136795A (en) * 1998-11-18 2000-10-24 Omni Nutraceuticals, Inc Dietary regimen of nutritional supplements for relief of symptoms of arthritis
EP1207862A2 (fr) * 1999-06-07 2002-05-29 The University Of Sheffield Traitement de l'arthrite

Also Published As

Publication number Publication date
WO2003000191A3 (fr) 2004-03-11
EP1423081A2 (fr) 2004-06-02
WO2003000191A2 (fr) 2003-01-03
JP2005521629A (ja) 2005-07-21
EP1423081A4 (fr) 2005-05-25

Similar Documents

Publication Publication Date Title
CA2451248A1 (fr) Composition comprenant des glycosaminoglycanes et des inhibiteurs d'hyaluronidase destinee au traitement d'articulations arthritiques
US20050123593A1 (en) Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
Girish et al. The magic glue hyaluronan and its eraser hyaluronidase: a biological overview
EP2786782B1 (fr) Acide hyaluronique sulfaté destiné au traitement de l'arthrose dégénérative
Gandhi et al. Heparin/heparan sulphate-based drugs
US10821131B2 (en) Pharmaceutical formulations comprising chondroitin sulfate and hyaluronic acid derivatives
CA2598331C (fr) Derives d'amide d'acide hyaluronique pour l'osteoarthrose
CA2426083A1 (fr) Utilisation de derives d'acide hyaluronique pour inhiber l'arthrite inflammatoire
Lu et al. Different molecular weights of hyaluronan research in knee osteoarthritis: A state-of-the-art review
M Hiebert Proteoglycans and diabetes
KR102007554B1 (ko) N-탈황화된 글리코스아미노글리칸 유도체 및 약물로서의 용도
Fakhari Biomedical application of hyaluronic acid nanoparticles
ES2281265B1 (es) Composiciones para el tratamiento de la artrosis.
JPH11269077A (ja) ホスホリパーゼａ２阻害用医薬組成物
EP1379135B1 (fr) Formulations comprenant des ingredients actifs pieges et utilisations de ces formulations
JP4786149B2 (ja) ギャップ機能抑制剤、細胞増殖促進剤及び硫酸化ポリフコース
AU2002255993A1 (en) Formulations comprising entrapped active ingredients and uses thereof
AU2002312564A1 (en) Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints
Gustafson The influence of sulfated polysaccharides on the circulating levels of hyaluronan
EP3142749B1 (fr) Composition de viscosupplément comprenant des ulvanes pour le traitement de l'arthrite
JP2004210714A (ja) 骨疾患治療剤
AU2002312563A1 (en) Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
PRIMER WILL THE REAL HYALURONAN PLEASE STAND UP?

Legal Events

Date Code Title Description
FZDE Dead